InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,475.09
(
0.27%
)
US TECH 100
19,187.20
(
-0.46%
)
Dow Jones
39,169.52
(
0.13%
)
Brent Oil
87.10
(
0.65%
)
Bitcoin
62,636.17
(
-0.34%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: JJM760 post# 7187

Wednesday, 04/20/2011 11:11:27 AM

Wednesday, April 20, 2011 11:11:27 AM

Post# of 80490
Imo, most of the recent run-up was due to the reduced uncertainty associated with whether Merck intends to file the NDA. First, Merck stopped the endometrial trial early, second, the SUCCEED trial met its primary end point,and third, Ariad exercised its co-promote option. I'm looking for the cohort data to remove any remaining uncertainty.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up